SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: TechNavio | PRODUCT CODE: 2172492

Cover Image

PUBLISHER: TechNavio | PRODUCT CODE: 2172492

Global Dravet Syndrome Treatment Market 2026-2030

PUBLISHED:
PAGES: 294 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 2500
PDF (Enterprise License)
USD 4000

Add to Cart

The global dravet syndrome treatment market is forecasted to grow by USD 972.9 mn during 2025-2030, accelerating at a CAGR of 11.8% during the forecast period. The report on the global dravet syndrome treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by expanding genetic testing and early molecular diagnosis, regulatory incentives and orphan drug fast-tracking, transition toward disease-modifying genetic and antisense oligonucleotide platforms.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Market Scope
Base Year2025
End Year2030
Series Year2026-2030
Growth MomentumAccelerate
YOY 202610.6%
CAGR11.8%
Incremental Value$972.9 mn

Technavio's global dravet syndrome treatment market is segmented as below:

By Product

  • SGDs
  • TGDs
  • FGDs

By Diagnostic Methods

  • Magnetic resonance imaging
  • Electroencephalography
  • SCN1A genetic testing
  • Others

By Distribution Channel

  • Hospital pharmacy
  • Retail pharmacy
  • E-commerce
  • Others

Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • The Netherlands
  • Asia
  • Rest of World (ROW)
  • Rest of World (ROW)

This study identifies the commercialization of precision antisense RNA therapies as one of the prime reasons driving the global dravet syndrome treatment market growth during the next few years. Also, development of cell-selective AAV gene therapy vectors and integration of wearable seizure telemetry and digital biomarkers will lead to sizable demand in the market.

The report on the global dravet syndrome treatment market covers the following areas:

  • Global dravet syndrome treatment market sizing
  • Global dravet syndrome treatment market forecast
  • Global dravet syndrome treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global dravet syndrome treatment market vendors that include BIOCODEX SAS, Bloom Science, Eisai Co. Ltd., Emugen Therapeutics, Encoded Therapeutics Inc., H. Lundbeck AS, Harmony Biosciences Holdings Inc., IAMA Therapeutics, Ionis Pharmaceuticals Inc., Jazz Pharmaceuticals Plc, Neuroene Therapeutics, PTC Therapeutics Inc., Regel Therapeutics, Stoke Therapeutics Inc., Tacit Therapeutics, Takeda Pharmaceutical Ltd., Tevard Biosciences, UCB SA. Also, the global dravet syndrome treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR45344

Table of Contents

1 Executive Summary

  • 1.1 Market overview
    • Executive Summary - Chart on Market Overview
    • Executive Summary - Data Table on Market Overview
    • Executive Summary - Chart on Global Market Characteristics
    • Executive Summary - Chart on Market by Geography
    • Executive Summary - Chart on Market Segmentation by Product
    • Executive Summary - Chart on Market Segmentation by Diagnostic Methods
    • Executive Summary - Chart on Market Segmentation by Distribution Channel
    • Executive Summary - Chart on Incremental Growth
    • Executive Summary - Data Table on Incremental Growth
    • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

  • 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
    • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • 2.2 Criticality of inputs and Factors of differentiation
  • 2.3 Factors of disruption
  • 2.4 Impact of drivers and challenges

3 Market Landscape

  • 3.1 Market ecosystem
  • 3.2 Market characteristics
  • 3.3 Value chain analysis

4 Market Sizing

  • 4.1 Market definition
  • 4.2 Market segment analysis
    • Market segments
  • 4.3 Market size 2025
  • 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

  • 5.1 Global Dravet Syndrome Treatment Market 2020 - 2024
    • Historic Market Size - Data Table on Global Dravet Syndrome Treatment Market 2020 - 2024 ($ million)
  • 5.2 Product segment analysis 2020 - 2024
    • Historic Market Size - Product Segment 2020 - 2024 ($ million)
  • 5.3 Diagnostic Methods segment analysis 2020 - 2024
    • Historic Market Size - Diagnostic Methods Segment 2020 - 2024 ($ million)
  • 5.4 Distribution Channel segment analysis 2020 - 2024
    • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
  • 5.5 Geography segment analysis 2020 - 2024
    • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
  • 5.6 Country segment analysis 2020 - 2024
    • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

  • 6.1 Impact of AI on global dravet syndrome treatment market
  • 6.2 Impact of geopolitical conflicts on global dravet syndrome treatment market

7 Five Forces Analysis

  • 7.1 Five forces summary
    • Five forces analysis - Comparison between 2025 and 2030
  • 7.2 Bargaining power of buyers
    • Bargaining power of buyers - Impact of key factors 2025 and 2030
  • 7.3 Bargaining power of suppliers
    • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
  • 7.4 Threat of new entrants
    • Threat of new entrants - Impact of key factors in 2025 and 2030
  • 7.5 Threat of substitutes
    • Threat of substitutes - Impact of key factors in 2025 and 2030
  • 7.6 Threat of rivalry
    • Threat of rivalry - Impact of key factors in 2025 and 2030
  • 7.7 Market condition

8 Market Segmentation by Product

  • 8.1 Market segments
  • 8.2 Comparison by Product
  • 8.3 SGDs - Market size and forecast 2025-2030
  • 8.4 TGDs - Market size and forecast 2025-2030
  • 8.5 FGDs - Market size and forecast 2025-2030
  • 8.6 Market opportunity by Product
    • Market opportunity by Product ($ million)

9 Market Segmentation by Diagnostic Methods

  • 9.1 Market segments
  • 9.2 Comparison by Diagnostic Methods
  • 9.3 Magnetic resonance imaging - Market size and forecast 2025-2030
  • 9.4 Electroencephalography - Market size and forecast 2025-2030
  • 9.5 SCN1A genetic testing - Market size and forecast 2025-2030
  • 9.6 Others - Market size and forecast 2025-2030
  • 9.7 Market opportunity by Diagnostic Methods
    • Market opportunity by Diagnostic Methods ($ million)

10 Market Segmentation by Distribution Channel

  • 10.1 Market segments
  • 10.2 Comparison by Distribution Channel
  • 10.3 Hospital pharmacy - Market size and forecast 2025-2030
  • 10.4 Retail pharmacy - Market size and forecast 2025-2030
  • 10.5 E-commerce - Market size and forecast 2025-2030
  • 10.6 Others - Market size and forecast 2025-2030
  • 10.7 Market opportunity by Distribution Channel
    • Market opportunity by Distribution Channel ($ million)

11 Customer Landscape

  • 11.1 Customer landscape overview
    • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

  • 12.1 Geographic segmentation
  • 12.2 Geographic comparison
  • 12.3 North America - Market size and forecast 2025-2030
    • 12.3.1 US - Market size and forecast 2025-2030
    • 12.3.2 Canada - Market size and forecast 2025-2030
    • 12.3.3 Mexico - Market size and forecast 2025-2030
  • 12.4 Europe - Market size and forecast 2025-2030
    • 12.4.1 Germany - Market size and forecast 2025-2030
    • 12.4.2 UK - Market size and forecast 2025-2030
    • 12.4.3 France - Market size and forecast 2025-2030
    • 12.4.4 Italy - Market size and forecast 2025-2030
    • 12.4.5 Spain - Market size and forecast 2025-2030
    • 12.4.6 The Netherlands - Market size and forecast 2025-2030
  • 12.5 Asia - Market size and forecast 2025-2030
    • 12.5.1 China - Market size and forecast 2025-2030
    • 12.5.2 Japan - Market size and forecast 2025-2030
    • 12.5.3 India - Market size and forecast 2025-2030
    • 12.5.4 South Korea - Market size and forecast 2025-2030
    • 12.5.5 Indonesia - Market size and forecast 2025-2030
    • 12.5.6 Thailand - Market size and forecast 2025-2030
  • 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
    • 12.6.1 Brazil - Market size and forecast 2025-2030
    • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
    • 12.6.3 UAE - Market size and forecast 2025-2030
    • 12.6.4 Turkey - Market size and forecast 2025-2030
    • 12.6.5 Argentina - Market size and forecast 2025-2030
    • 12.6.6 South Africa - Market size and forecast 2025-2030
    • 12.6.7 Colombia - Market size and forecast 2025-2030
    • 12.6.8 Israel - Market size and forecast 2025-2030
  • 12.7 Market opportunity by geography
    • Market opportunity by geography ($ million)
    • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

  • 13.1 Market drivers
    • Expanding genetic testing and early molecular diagnosis
    • Regulatory incentives and orphan drug fast-tracking
    • Transition toward disease-modifying genetic and antisense oligonucleotide platforms
  • 13.2 Market challenges
    • Exorbitant pricing structures and reimbursement friction
    • Refractory seizure profiles and polypharmacy adverse events
    • Severe non-seizure comorbidities and diagnostic latency
  • 13.3 Impact of drivers and challenges
    • Impact of drivers and challenges in 2025 and 2030
  • 13.4 Market opportunities
    • Commercialization of precision antisense RNA therapies
    • Development of cell-selective AAV gene therapy vectors
    • Integration of wearable seizure telemetry and digital biomarkers

14 Competitive Landscape

  • 14.1 Overview
  • 14.2 Competitive Landscape
    • Overview on criticality of inputs and factors of differentiation
  • 14.3 Landscape disruption
    • Overview on factors of disruption
  • 14.4 Industry risks
    • Impact of key risks on business

15 Competitive Analysis

  • 15.1 Companies profiled
    • Companies covered
  • 15.2 Company ranking index
    • Company ranking index
  • 15.3 Market positioning of companies
    • Matrix on companies position and classification
  • 15.4 BIOCODEX SAS
    • BIOCODEX SAS - Overview
    • BIOCODEX SAS - Product / Service
    • BIOCODEX SAS - Key offerings
    • SWOT
  • 15.5 Bloom Science
    • Bloom Science - Overview
    • Bloom Science - Product / Service
    • Bloom Science - Key offerings
    • SWOT
  • 15.6 Eisai Co. Ltd.
    • Eisai Co. Ltd. - Overview
    • Eisai Co. Ltd. - Business segments
    • Eisai Co. Ltd. - Key offerings
    • Eisai Co. Ltd. - Segment focus
    • SWOT
  • 15.7 Emugen Therapeutics
    • Emugen Therapeutics - Overview
    • Emugen Therapeutics - Product / Service
    • Emugen Therapeutics - Key offerings
    • SWOT
  • 15.8 Encoded Therapeutics Inc.
    • Encoded Therapeutics Inc. - Overview
    • Encoded Therapeutics Inc. - Product / Service
    • Encoded Therapeutics Inc. - Key offerings
    • SWOT
  • 15.9 H. Lundbeck AS
    • H. Lundbeck AS - Overview
    • H. Lundbeck AS - Product / Service
    • H. Lundbeck AS - Key offerings
    • SWOT
  • 15.10 Harmony Biosciences Holdings Inc.
    • Harmony Biosciences Holdings Inc. - Overview
    • Harmony Biosciences Holdings Inc. - Product / Service
    • Harmony Biosciences Holdings Inc. - Key offerings
    • SWOT
  • 15.11 IAMA Therapeutics
    • IAMA Therapeutics - Overview
    • IAMA Therapeutics - Product / Service
    • IAMA Therapeutics - Key offerings
    • SWOT
  • 15.12 Ionis Pharmaceuticals Inc.
    • Ionis Pharmaceuticals Inc. - Overview
    • Ionis Pharmaceuticals Inc. - Product / Service
    • Ionis Pharmaceuticals Inc. - Key offerings
    • SWOT
  • 15.13 Jazz Pharmaceuticals Plc
    • Jazz Pharmaceuticals Plc - Overview
    • Jazz Pharmaceuticals Plc - Product / Service
    • Jazz Pharmaceuticals Plc - Key news
    • Jazz Pharmaceuticals Plc - Key offerings
    • SWOT
  • 15.14 Neuroene Therapeutics
    • Neuroene Therapeutics - Overview
    • Neuroene Therapeutics - Product / Service
    • Neuroene Therapeutics - Key offerings
    • SWOT
  • 15.15 PTC Therapeutics Inc.
    • PTC Therapeutics Inc. - Overview
    • PTC Therapeutics Inc. - Business segments
    • PTC Therapeutics Inc. - Key news
    • PTC Therapeutics Inc. - Key offerings
    • PTC Therapeutics Inc. - Segment focus
    • SWOT
  • 15.16 Takeda Pharmaceutical Ltd.
    • Takeda Pharmaceutical Ltd. - Overview
    • Takeda Pharmaceutical Ltd. - Business segments
    • Takeda Pharmaceutical Ltd. - Key news
    • Takeda Pharmaceutical Ltd. - Key offerings
    • Takeda Pharmaceutical Ltd. - Segment focus
    • SWOT
  • 15.17 Tevard Biosciences
    • Tevard Biosciences - Overview
    • Tevard Biosciences - Product / Service
    • Tevard Biosciences - Key offerings
    • SWOT
  • 15.18 UCB SA
    • UCB SA - Overview
    • UCB SA - Product / Service
    • UCB SA - Key news
    • UCB SA - Key offerings
    • SWOT

16 Appendix

  • 16.1 Scope of the report
    • Market definition
    • Objectives
    • Notes and caveats
  • 16.2 Inclusions and exclusions checklist
    • Inclusions checklist
    • Exclusions checklist
  • 16.3 Currency conversion rates for US$
    • Currency conversion rates for US$
  • 16.4 Research methodology
    • Research methodology
  • 16.5 Data procurement
    • Information sources
  • 16.6 Data validation
    • Data validation
  • 16.7 Validation techniques employed for market sizing
    • Validation techniques employed for market sizing
  • 16.8 Data synthesis
    • Data synthesis
  • 16.9 360 degree market analysis
    • 360 degree market analysis
  • 16.10 List of abbreviations
    • List of abbreviations
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!